Welcome to our dedicated page for ARCH THERAPEUTICS news (Ticker: ARTH), a resource for investors and traders seeking the latest updates and insights on ARCH THERAPEUTICS stock.
Arch Therapeutics, Inc., a biotechnology company based in the United States, focuses on developing and marketing products utilizing its AC5 self-assembling technology platform. The company's products aim to stop bleeding, control leaking, and manage wounds during surgery, trauma, or from disease. Arch Therapeutics offers flagship products like the AC5 Advanced Wound System and AC5 Topical Hemostat for skin applications. Founded in 2006, the company is headquartered in Framingham, Massachusetts.
Arch Therapeutics (OTCQB: ARTH) presented at the Symposium on Advanced Wound Care on October 31, 2021, showcasing the AC5® Advanced Wound System. This innovative technology aids in managing chronic and biofilm-infected wounds, enhancing healing outcomes. Key opinion leaders affirm its unique self-assembling properties that promote optimal debridement and wound treatment. Arch's regulatory approvals for its products bolster its market position in the wound care sector. The company continues to explore new commercial opportunities and clinical data contributions.
Arch Therapeutics (OTCQB: ARTH) announced that its AC5® Advanced Wound System will be featured at the 2021 Symposium on Advanced Wound Care (SAWC) Fall, taking place from October 29-31, 2021 in Las Vegas. The presentation, scheduled for October 31 from 11:20 AM-12:20 PM PT, will showcase AC5® for chronic and non-healing wounds. Over 1,400 wound care specialists are expected to attend. Arch aims to demonstrate how AC5® can enhance patient outcomes and reduce treatment costs.
Arch Therapeutics (OTCQB: ARTH) announced the launch of its Experts in Wound Care Program, featuring interviews with key opinion leaders aimed at enhancing wound care practices. The first interview, aligned with International Infection Prevention Week, discusses chronic wound management with Dr. Randall Wolcott. The program seeks to improve patient outcomes and lower healthcare costs through innovative practices and products like AC5® Advanced Wound System. This initiative underlines Arch's commitment to advancing wound care and enhancing care quality.
Arch Therapeutics, Inc. (OTCQB: ARTH) announced progress in its commercialization efforts during the LD Micro Main Event XIV investor conference on October 13, 2021. The company achieved its first sale to a Veterans Administration hospital through Lovell Government Services. Noteworthy improvements include gaining access to more healthcare facilities and inclusion on purchasing schedules necessary for VA transactions. CEO Terry Norchi highlighted the team's steady progress and expressed optimism about driving incremental revenue. Arch is focused on advancing its self-assembling wound care technology.
Arch Therapeutics will present at the LD Micro Main Event XIV from October 12-14, 2021, at the Luxe Sunset Boulevard Hotel, Los Angeles. CEO Terrence W. Norchi and CFO Michael S. Abrams are scheduled to provide a corporate update on October 13, 2021, at 1:30 PM PT (4:30 PM ET). The presentation will be accessible on demand via their website. Arch Therapeutics develops innovative wound care solutions, including AC5® Advanced Wound System, already authorized for marketing in the US and Europe.
Arch Therapeutics (OTCQB: ARTH) has launched a coverage and reimbursement pilot for its AC5® Advanced Wound System in collaboration with The Reimbursement Group. This pilot aims to establish initial coverage standards with CMS and private payors over the next six months. The initiative complements Arch's partnership with Lovell Government Services and its ongoing efforts to develop unique CPT codes for AC5®. The company emphasizes its commitment to commercialization in both government and private sectors.
Arch Therapeutics has appointed Larry Hicks to its Board of Directors, bringing over 30 years of experience in the medical device industry. Hicks, currently the CEO of Healthcare Components Group, has held leadership roles at several notable companies. CEO Terrence W. Norchi expressed confidence in Hicks' ability to drive sales and enhance the company's commercialization efforts. Arch Therapeutics develops innovative wound care and biosurgical devices, including the AC5® Advanced Wound System, which has received regulatory approval in the U.S. and Europe.
Arch Therapeutics (OTCQB: ARTH) has entered a non-exclusive distribution agreement with Lovell Government Services to enhance sales of its AC5® Advanced Wound System in U.S. governmental medical facilities. This partnership targets inclusion on federal supply schedules, aiming for improved market access. Concurrently, Arch has terminated its exclusive agreement with Buffalo Supply. The collaboration with Lovell, a Service-Disabled Veteran-Owned Small Business, is expected to expedite access to contracting channels within the Veterans Affairs hospitals.
Arch Therapeutics has appointed Dan Yrigoyen as Vice President of Sales to spearhead its national commercialization efforts. With over 25 years in healthcare, including roles at Medela and Hollister, Yrigoyen is expected to enhance revenue generation and channel development. CEO Terrence W. Norchi expressed confidence in Yrigoyen's ability to drive immediate results. Arch is focused on developing novel wound care and biosurgical devices, including its AC5 technology, which has received regulatory approval in the U.S. and Europe.
Arch Therapeutics, Inc. (OTCQB: ARTH) has announced its participation in the Ladenburg Thalmann 2021 Healthcare Conference, scheduled for July 13-14, 2021. CEO Terry Norchi will provide a corporate update and participate in a Q&A session on July 13 at 12:00 PM EDT. Investors can access the live webcast here. Arch Therapeutics specializes in innovative wound care and biosurgical devices, including its AC5 Advanced Wound System and AC5 Topical Hemostat, which are already in commercial use.
FAQ
What is the current stock price of ARCH THERAPEUTICS (ARTH)?
What is the market cap of ARCH THERAPEUTICS (ARTH)?
What does Arch Therapeutics, Inc. do?
Where is Arch Therapeutics, Inc. headquartered?
When was Arch Therapeutics, Inc. founded?
What are the flagship products of Arch Therapeutics, Inc.?
What is the focus of products developed by Arch Therapeutics, Inc.?
What is the contact information for Arch Therapeutics, Inc. Investor Relations?
Who is the Chief Financial Officer of Arch Therapeutics, Inc.?
What are the investigational devices offered by Arch Therapeutics, Inc.?
What are the trademarks associated with Arch Therapeutics, Inc.?
What is a significant milestone planned by Arch Therapeutics, Inc.?
